Three of the molecular subgroups are strongly linked to clinical and genetic features that are known to be prognostic in neuroblastoma [1], with greater than 90% of groups 2, 3 and 4 exhibiting MYCN amplification, 11q deletion or infant diagnosis, respectively. Here, MYCN is linked to neuroblastoma.